Milordini et al. report the design of DNA aptamers that block RAD51-BRCA2 interaction and impair DNA repair in cancer cells. Combined with the PARP inhibitor Olaparib, they trigger synthetic lethality, suggesting potential avenues for cancer treatment.
- Giulia Milordini
- Elsa Zacco
- Gian Gaetano Tartaglia
